Preliminary results from a Phase 1 study presented at ESMO GI 2026 evaluated the combination of zoldonrasib and daraxonrasib for treating second-line or later KRAS G12D-mutant metastatic pancreatic adenocarcinoma. The trial aimed to determine if the dual RAS(ON) inhibitor strategy could improve outcomes over standard chemotherapy, which typically yields low response rates in this aggressive cancer.